| 3.01 0.04 (1.35%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.75 | 1-year : | 4.21 |
| Resists | First : | 3.21 | Second : | 3.6 |
| Pivot price | 3.02 |
|||
| Supports | First : | 2.57 | Second : | 2.14 |
| MAs | MA(5) : | 2.85  |
MA(20) : | 3.05 |
| MA(100) : | 3.9 |
MA(250) : | 3.62 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 36.1 |
D(3) : | 24.7 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 7.94 | Low : | 1.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VVOS ] has closed above bottom band by 48.0%. Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.06 - 3.07 | 3.07 - 3.08 |
| Low: | 2.91 - 2.93 | 2.93 - 2.95 |
| Close: | 2.98 - 3.01 | 3.01 - 3.04 |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Fri, 03 Oct 2025
Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders - MSN
Wed, 17 Sep 2025
77% Success Rate: Vivos' Non-Surgical Device Transforms Sleep Apnea Treatment for Millions of Children - Stock Titan
Tue, 19 Aug 2025
$500K Revenue in Just 20 Days: Vivos' New Sleep Center Acquisition Shows Strong Early Results in Q2 2025 - Stock Titan
Tue, 19 Aug 2025
Vivos Therapeutics Shifts Strategy Amid Financial Challenges - TipRanks
Tue, 19 Aug 2025
Earnings call transcript: Vivos Therapeutics reports Q2 2025 earnings miss - Investing.com
Wed, 30 Jul 2025
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 8 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 29.5 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 580 (K) |
| Shares Short P.Month | 194 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | -99.5 % |
| Operating Margin | -127.4 % |
| Return on Assets (ttm) | -42.5 % |
| Return on Equity (ttm) | -262.1 % |
| Qtrly Rev. Growth | -5.9 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 1.91 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -2.6 |
| PEG Ratio | 0 |
| Price to Book value | 4.77 |
| Price to Sales | 1.56 |
| Price to Cash Flow | -1.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|